

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Sinopharm Tech Holdings Limited

### 國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

**(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING;  
(2) EFFECTIVE DATES OF THE SHARE CONSOLIDATION  
AND CHANGE IN BOARD LOT SIZE;  
AND  
(3) ADJUSTMENTS TO THE OUTSTANDING SHARE OPTIONS**

References are made to the circular (the “**Circular**”) of Sinopharm Tech Holdings Limited (the “**Company**”) and the notice (the “**Notice**”) of the extraordinary general meeting of the Company (the “**EGM**”), both dated 10 August 2023, and the announcement of the Company dated 18 August 2023. Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Circular. All Directors attended the EGM in person or by electronic means.

#### **POLL RESULTS OF THE EGM**

The Board is pleased to announce that at the EGM held on Friday, 25 August 2023, the proposed ordinary resolution (the “**Resolution**”) as set out in the Notice was duly passed by the Shareholders by way of poll.

The poll results in respect of the Resolution are as follows:

<b>ORDINARY RESOLUTION*</b>		<b>Number of Votes (%)</b>	
		<b>For</b>	<b>Against</b>
1.	(a) every twenty five (25) issued and unissued ordinary shares of par value of HK\$0.0125 each in the share capital of the Company be consolidated into one (1) consolidated share (the “ <b>Consolidated Share</b> ”) of par value of HK\$0.3125 each (the “ <b>Share Consolidation</b> ”), such Consolidated Shares shall rank pari passu in all respects with each other and have the rights and privileges and be subject to the restrictions as contained in the memorandum and articles of association of the Company;	1,421,475,964 (100.00%)	0 (0.00%)

	<p>(b) following the Share Consolidation, any one of the directors of the Company (the “<b>Director(s)</b>”) be and is hereby authorised to make arrangements for the settlement and disposal of fractional entitlements, if any, arising from or in connection therewith and, in particular (but without prejudice to the generality of the foregoing), by aggregating any fractional entitlements arising as a result thereof and selling the same for the benefits of the Company in such manner and on such terms as the Directors may think fit; and</p> <p>(c) any one or more of the Directors be and is hereby authorised to do all such acts and things and sign and execute all such documents for and on behalf of the Company, including under the common seal of the Company, where applicable, as he or they may consider necessary, desirable or expedient for the purpose of carrying out or giving effect to or otherwise arising from and/or in connection with the Share Consolidation.</p>		
--	--	--	--

\* Full text of the Resolution is set out in the Notice.

As more than 50% of the votes were cast in favour of the above Resolution, this Resolution was duly passed as ordinary resolution of the Company at the EGM.

Elite Partners CPA Limited, the auditors of the Company (the “**Auditor**”), was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As at the date of the EGM, the total issued share capital of the Company comprised 4,592,326,397 Existing Shares entitling the Shareholders to attend and vote on the Resolution at the EGM. No Shareholder was entitled to attend and abstain from voting in favour of the Resolution at the EGM as set out in Rule 17.47A of the GEM Listing Rules and no Shareholder was required under the GEM Listing Rules to abstain from voting.

**EFFECTIVE DATES OF THE SHARE CONSOLIDATION AND CHANGE IN BOARD LOT SIZE**

The Board is pleased to announce that the Share Consolidation and the Change in Board Lot Size will become effective on Tuesday, 29 August 2023 and Tuesday, 12 September 2023 respectively. Dealing in the Consolidated Shares in original and new board lots on the Stock Exchange will commence at 9:00 a.m. on Tuesday, 29 August 2023 and 9:00 a.m. on Tuesday, 12 September 2023 respectively.

Please refer to the Circular for details, including the trading arrangement, exchange of share certificates and matching services for odd lots in connection with the Share Consolidation and the Change in Board Lot Size.

**ADJUSTMENTS TO THE OUTSTANDING SHARE OPTIONS**

As at the date of this announcement, there are 239,000,000 outstanding Share Options entitling the holders thereof to subscribe for an aggregate of 239,000,000 Existing Shares under the Share Option Scheme. As a result of the Share Consolidation and in accordance with the Share Option Scheme, the

exercise price and the number of Consolidated Shares to be issued upon exercise of the outstanding Share Options will be adjusted as follows with effect from the effective date of the Share Consolidation (i.e. on Tuesday, 29 August 2023).

Name or category of participant	Date of grant	Exercisable period (both days inclusive)	Immediately prior to the adjustments as a result of completion of the Share Consolidation		Immediately after the adjustments as a result of completion of the Share Consolidation	
			Exercise price per Existing Share HK\$	Number of Existing Shares to be issued under the outstanding Share Options	Adjusted exercise price per Consolidated Share HK\$	Adjusted number of Consolidated Shares to be issued under the outstanding Share Options
<i>Executive Director:</i>						
Mr. CHAU Wai Wah Fred	28 December 2022	1 July 2023 to 30 June 2028	0.04	40,000,000	1.00	1,600,000
Mr. HO Kam Kin	28 December 2022	1 July 2023 to 30 June 2028	0.04	40,000,000	1.00	1,600,000
Ms. KWOK Shuk Yi	28 December 2022	1 July 2023 to 30 June 2028	0.04	40,000,000	1.00	1,600,000
<i>Non-executive Director:</i>						
Dr. CHENG Yanjie	28 December 2022	1 July 2023 to 30 June 2028	0.04	4,000,000	1.00	160,000
<i>Independent Non-executive Director:</i>						
Mr. LAU Fai Lawrence	28 December 2022	1 July 2023 to 30 June 2028	0.04	4,000,000	1.00	160,000
<i>Others:</i>						
Six employees	28 December 2022	1 July 2023 to 30 June 2028	0.04	111,000,000	1.00	4,440,000
				239,000,000		9,560,000

Save for the above adjustments, all other terms and conditions of the outstanding Share Options shall remain unchanged. As a result of the Share Consolidation, the maximum number of the Consolidated Shares which may fall to be issued upon exercise of the Shares Options to be granted under the scheme mandate limit of the Share Option Scheme will be adjusted to 7,821,507 Consolidated Shares.

The Auditor has certified in writing that the adjustments made to the exercise price of the outstanding Share Options and the number of the Consolidated Shares to be issued upon exercise of the outstanding Share Options are fair and reasonable and in accordance with (1) the terms of the Share Option Scheme; (2) Rule 23.03(13) of the GEM Listing Rules; and (3) the “Supplementary Guidance on Rule 23.03(13) of the GEM Listing Rules and the Note immediately after the Rule” attached to the Frequently Asked Question No. 072-2020 issued by the Stock Exchange on 6 November 2020 and updated on 1 January 2023.

By Order of the Board  
**Sinopharm Tech Holdings Limited**  
**國藥科技股份有限公司**  
**CHAU Wai Wah Fred**  
*Executive Director*

Hong Kong, 25 August 2023

*As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence and Mr. HSU Dong An as independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the GEM website at <https://www.hkgem.com> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.*